BridgeBio Will Present Encaleret Data in October
BridgeBio Pharma will share results from the CALIBRATE trial at the upcoming ASBMR meeting in Boston.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Should companies prioritize the development of new treatments for rare genetic conditions?
BridgeBio Pharma will present Phase 3 trial data for encaleret at the ASBMR 2026 Annual Meeting in Boston from October 9-12, 2026. The presentations will highlight the effects of the investigational drug on bone turnover and patient-reported outcomes.
Why it matters
Encaleret, which holds U.S. FDA Fast Track Designation, targets autosomal dominant hypocalcemia type 1 caused by CASR gene variants. These findings provide insight into a potential oral treatment for patients suffering from this genetic condition.
The upcoming presentations focus on a 24-week Phase 3 CALIBRATE trial duration. This study examines the impact of encaleret on bone turnover metrics and patient-reported outcomes for individuals with genetic CASR variants.
The players
BridgeBio Pharma
This commercial-stage biopharmaceutical company focuses on developing medicines for patients with genetic diseases and cancers.
HypoPARAthyroidism Association
This patient advocacy organization provides support, education, and research resources for individuals affected by hypoparathyroidism.
The details
BridgeBio Pharma also plans to share safety data concerning infigratinib, an investigational treatment for children with achondroplasia. Furthermore, the company collaborated with the HypoPARAthyroidism Association on regional family cascade genetic testing to advance research awareness.
Timeline
The ASBMR 2026 Annual Meeting will take place in Boston from October 9-12, 2026.
Posters covering symptom burden and genetic testing are scheduled for October 10, 2026.
Oral presentations regarding encaleret and an achondroplasia poster are slated for October 11, 2026.
Deeper Dive
The ASBMR 2026 Annual Meeting acts as the essential stage for sharing results from the 24-week CALIBRATE trial. This presentation updates the scientific community on BridgeBio Pharma’s approach to treating genetic CASR gene variants.
Patients and healthcare providers will gain critical information regarding the potential availability and efficacy of new oral treatment options. These findings could eventually alter how doctors manage the symptoms and genetic factors associated with specific rare conditions.
The takeaway
BridgeBio Pharma continues to push for new treatments in the rare genetic disease space through rigorous Phase 3 evaluation. Readers can follow these updates to understand how clinical milestones translate into future medical care pathways.
Further reading
Learn more about the latest research and clinical developments in Biotech.
Live Poll
Should companies prioritize the development of new treatments for rare genetic conditions?
